Post by Echosens

Name: We recently had the pleasure of sitting down with Prof. Dr. Jörn M. Schattenberg, a leading hepatolo
Uploaded: 2025-10-07T09:39:25.528Z
Channel: Echosens
Description: We recently had the pleasure of sitting down with Prof. Dr. Jörn M. Schattenberg, a leading hepatologist and gastroenterologist in Germany, to discuss the European Commission (EC) approval of Rezdiffr

27,481 followers

We recently had the pleasure of sitting down with Prof. Dr. Jörn M. Schattenberg, a leading hepatologist and gastroenterologist in Germany, to discuss the European Commission (EC) approval of Rezdiffra™ (resmetirom) as the first medication approved for people living with metabolic dysfunction-associated steatohepatitis (MASH) in the European Union. As a key investigator in the pivotal MAESTRO-NASH phase 3 trial, Prof. Dr. Schattenberg brings a unique perspective on what this milestone means for patients, providers, and the future of liver care. 🌟 He also shared his POV on the role of non-invasive tests like FibroScan® and why they are critical to identify and monitor patients for treatment with Rezdiffra™ (resmetirom). 🔗 Read the entire Q&A “A New Era for Liver Care: Prof. Dr. Jörn Schattenberg on the EC Approval of Rezdiffra™ for MASH” here: https://lnkd.in/eHu93Dbr #FibroScanVCTE #Rezdiffra #MASH #LiverHealthMatters

Video Content